Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
Momentum Public Relations
Press Release: February 05, 2019
Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients. This suspension does not affect the timing of the European application nor the development of the second-generation inhalation products.
Quality standards and process validations are imposed by pharmaceutical Good Manufacturing Practices (GMP). Just like our food chain, botanical drugs have unique challenges because of the potential for microbial contamination known as mycotoxins. Tetra’s investigational drug is composed of raw cannabis materials. In late spring 2018, Tetra initiated a study to monitor the microbial flora in its investigational product in order to validate the storage and drying process used in the fabrication of its investigational product. On December 20th the results of this ongoing study revealed the presence of the 3 mycotoxins in the lot of the investigational drug used for the clinical trials. Tetra communicated these findings within 24-hours of discovery to regulators and acted rapidly to ensure the safety and wellness of patients. As per discussions with Health Canada and the Ethics Review Board, Tetra contacted every patient involved in the ongoing clinical trials to suspend treatment and retrieve the investigational drugs.
Cannabis products that are ultimately sold in the recreational or medical market in Canada, are cultivated, processed and sold under the Cannabis Act, which are subject to Good Production Practices. Under the Good Production Practices, there is only a requirement to test for certain mycotoxins, namely aflatoxin and total content of mycotoxins. The cannabis raw materials purchased by Tetra for use in its investigational drug met the requirements under the Cannabis Act and Good Production Practices and tested below allowable limits.
However, Tetra is administering cannabis to patients as a drug for use in clinical trials which is governed by the requirements of the Food and Drugs Act and related Regulations. The fabrication, processing, packaging and sale of the investigational drug, must be conducted in accordance with the Good Manufacturing Practices (“GMPs”). Such GMPs require the validation of the storage and drying process to ensure the cannabis drug conforms to the quality standard of a prescription drug. Tetra, having acted in accordance with the requirements of the Food and Drugs Act and GMPs, detected the presence of mycotoxins other than aflatoxin in the experimental lot used for the validation. This led to the analyses of every lot being used in its clinical trials to verify for the presence of two other types of mycotoxins (Ochratoxin A, and DON (Deoxynivalenol; Vomitoxin) and the inclusion of this testing into the product specifications.
Tetra Bio-Pharma considers patient health and well-being to be non-negotiable. Tetra will take the next 6 months to assess the situation and propose a robust quality program to Health Canada so that Canadian patients taking its PPP001 prescription cannabis-derived drug are confident in the products’ quality and safety.
Tetra Bio-Pharma CEO and CSO Guy Chamberland holds a Ph.D. in Biomedical Sciences (toxicology) among other academic designations and is a well-respected expert in the field particularly in drug safety stated, “This unexpected development will result in a 6-month delay in the submission of the Canadian New Drug Submission or Drug Identification Number (DIN) application for PPP001. Tetra strongly believes that this delay will lead to a safer and higher quality drug for patients with advanced cancer. Through our research and development efforts, Tetra’s intention is to create higher quality for all cannabis-derived medicinal products. This is Tetra’s commitment to patient safety. We will continue to provide reports to Health Canada so that the Canadian government receives Tetra’s data in a timely manner so that regulators can ensure the safety and wellness of all Canadians consuming recreational and medical cannabis.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Momentum Public Relations
Press Release: January 30, 2019
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Canada NewsWire
ORLEANS, ON, Jan. 30, 2019
The Proposed Transaction is expected to:
- provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabinoid company;
- provide Tetra with more pharmaceutical and natural health products;
- allow Tetra to sell these products worldwide;
- give Tetra access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
ORLEANS, ON, Jan. 30, 2019/CNW Telbec/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSXV: TBP) (OTCQB: TBPMF), today announced it has entered into a definitive agreement (the “Agreement“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“). Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “In completing this acquisition of Panag Pharma we have not only acquired a large portfolio of cannabinoid derived pharmaceutical and natural health products but also a team of scientists that have a substantial amount of expertise in the field. Tetra Bio-Pharma looks forward to incorporating Panag into its operations and accelerating its various drug development programs including our second-generation inhaled program.”
Following the closing of the Proposed Transaction, it is expected that Panag will remain a separate subsidiary owned 100% by Tetra and provide Tetra with additional discovery and early phase drug development capacity. With this robust product pipeline, Tetra intends to continue to implement its out-licensing program to generate additional revenues via upfront payments, milestone payments, and royalties and actively pursue the clinical development of lead products.
According to Dr. Orlando Hung, a co-founder of Panag, “The Panag team is very excited to have this well-timed opportunity with Tetra Bio-Pharma, allowing us to continue our decades of translational cannabinoid research. Utilizing the expertise and support from Tetra Bio-Pharma, we are confident that our partnership and combined skills will position us to bring effective and safe cannabinoid-based medications, as well as more innovative cannabinoid delivery systems to market to help managing patients with pain and inflammation.”
Pursuant to the Agreement, Tetra would acquire 100% of the issued and outstanding shares of Panag for an aggregate consideration of $12,000,000, on a debt-free basis and subject to customary post-closing adjustments. The purchase price would be payable by Tetra delivering to the Vendors, on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra (“Common Shares“), at a price per Common Share equal to the lesser of (i) the 10-day volume weighted average price of the Common Shares ending as of the date of the Agreement and (ii) the Discounted Market Price (as that term is defined in the policies of the TSX Venture Exchange (“TSXV“)) of the Common Shares as at the date that is three business days prior to the closing date of the Proposed Acquisition. The Agreement also contemplates the payment by Tetra to the Vendors of an aggregate amount of up to $15,000,000 in cash in milestone payments upon the achievement of operational targets associated with marketing approvals and commercialization of both human and veterinary drug products by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Tetra is committed to fund Panag’s research in an amount no less than $1,200,000 annually for a period of ten years after the closing date of the Proposed Acquisition. The milestone payments would be accelerated in the event of a bankruptcy, insolvency, failure of Tetra to make its funding commitments to Panag, change of control or sale of all of the assets of Tetra at any time until December 31, 2028. In addition, in the event of a change of control of Tetra within 24 months of the closing date of the Proposed Acquisition, the Vendors would be entitled to receive from Tetra an additional $10 million.
Two of the Vendors, Bill Cheliak and Gregory Drohan, are non-arm’s length parties to Tetra within the meaning of the rules of the TSXV. Mr. Cheliak is the Chairman of the board of directors of the Company (the “Board“) and Mr. Drohan is a director of the Company. The Proposed Transaction will not result in the issuance of securities to non-arm’s length parties as a group as payment of the purchase price exceeding 10% of the number of outstanding shares of the Company on a non-diluted basis.
The Board formed a special committee (the “Special Committee“) for purposes of evaluating the Proposed Transaction. The Special Committee was composed of Benoit Chotard and Carl Merton, both of whom have no interest in Panag or the Proposed Transaction. On December 24, 2018, the Special Committee received a fairness opinion (the “Fairness Opinion“) from Paradigm Capital stating that the purchase price under the Proposed Transaction is fair, from a financial point of view, to the shareholders of Tetra. In light of the Fairness Opinion and of other considerations and upon the recommendation of the Special Committee, the Board approved the Proposed Transaction. Because of their interests in the Proposed Transaction, Mr. Cheliak and Mr. Drohan recused themselves from all meetings and discussions of the Board relating to the Proposed Transaction and abstained from voting on the resolutions of the Board approving the Proposed Transaction.
The Company expects that the Proposed Transaction will be completed in February 2019. Completion of the Proposed Transaction remains subject to a number of conditions, including the receipt of the approval of the TSXV and such other closing conditions as are customary in transactions of this nature. There can be no assurance that such conditions will be satisfied and that the Proposed Transaction will be completed as described or at all.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Cannara has cash, equivalents of $43.5M at Nov. 30
Momentum Public Relations
Press Release: January 29, 2019
Cannara Biotech Inc. (“Cannara” or the “Company”) (CSE: LOVE), is building a vertically integrated Cannabis company focused on cannabis derivative products, today announced its financial results for the three-month period ended November 30, 2018.
Q1 2019 HIGHLIGHTS
- Subsequent to quarter end, began trading on the CSE
- Cash and cash equivalents of $43.5 million at end of Q1
- Revenue from short-term leases of $518,443
- Dual share structure dissolved upon public listing resulting in a single class of common shares
“On January 14th, Cannara became a publicly traded cannabis company, marking a critical milestone for our company,” said Zohar Krivorot, President and CEO of Cannara. “As this release represents our first disclosure as a public company, we want to assure the investment community we understand that being public demands transparency, which is entirely consistent with our values of respect and integrity. As we grow, we will stay true to our aim of building a premier cannabis company, we will maintain these core values.”
Construction of the Company’s Farnham, Quebec facility continues to be a top priority for Cannara with steady progress made throughout the quarter. Recently, the Company expanded the scope of Phase One to include a slightly larger growth area and additional processing capabilities, including some R&D space and equipment. With an estimated annual capacity of 15,000 kg of cannabis to be completed in the first half of 2019, the Farnhamfacility represents a key plank in the Company’s strategy to attract and grow via joint ventures with industry leaders.
“With a comprehensive brand strategy, our large one-of-kind facility, strong balance sheet and an elite senior management team, the fundamentals that will define Cannara are rapidly taking shape,” continued Mr. Krivorot. “Our expanding profile is accelerating our business development initiatives, positioning 2019 to be eventful and transformative year for us as we prepare for the upcoming legalization of beverages and other derivative cannabis products.”
“We are in the enviable position of having our Phase One construction and capacity plans fully funded, allowing us to pursue our strategic growth with confidence,” said Lennie Ryer, CFO of Cannara. “No doubt we are in the early stages of our growth curve, however, with $55 million raised in 2018, including our recently closed oversubscribed go-public round, our progress is speaking to our potential.”
About Cannara Biotech Inc.
Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility located in Farnham, less than 45 minutes from downtown Montreal. Leveraging Quebec’s low electricity costs, Cannara’s facility will produce high-grade indoor cannabis and derivative products for the Canadian and international markets. Working with partners from various industries, Cannara will generate licensing revenues, rental revenues and revenue streams from joint-venture arrangements leveraging this highly valuable property. For more information, visit our website: www.cannara.ca
ON BEHALF OF THE BOARD OF DIRECTORS
“Zohar Krivorot”
Zohar Krivorot
CEO and Director
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/cannara-biotech-reports-first-quarter-results-300785779.html
SOURCE Cannara Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/January2019/29/c3699.html
Contact:
Sabrina Williams, Communications Manager, sabrina.williams@cannara.ca, T: 514-543-4200 ext. 265; Zohar Krivorot, President & CEO, zohar@cannara.ca; Lennie Ryer CPA, CA, CFE, Chief Financial Officer, lennie@cannara.ca
- Published in Cannabis, Cannara, Marijuana, Medical Marijuana, News Home
CROP Farm to Produce 50 L of THC Oil and Applies for Chula Vista Dispensary Location
Momentum Public Relations
Press Release: January 24, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it will, initially, be making 100,000 premium Moon Rock Cones at one of its California subsidiaries as it expands its footprint in the state.
The raw material will be finished cannabis from CROP’s Humboldt County farm which is trimmed, high grade flower and will be for distillate input for cartridges and pre-rolls cones that will then be dipped in kief (cannabis crystals) to make the infused cones. The infused cones will be Hempire and Evolution branded with custom filters bearing the name. Additional equipment to fulfill the order is expected to arrive shortly.
After some initial market research, the company has established the best-selling SKUS are cones and pens. The company has instructed its toll process partner to convert equivalent material to produce approximately 50 liters of oil to fill 75,000 half gram cartridges and 50,000 quarter gram disposable pens, as well as the company will roll and tube approximately 200,000 Hempire and evolution branded 1-gram infused cones.
The distributor has offices in Oakland and Orange County. The distribution network consists of approximately 350 licensed cannabis stores across California.
The farm will shortly be taking down an additional 10,000 sq. ft. of canopy crop for harvest. Additionally, the company has retained local engineers to plan and permit the 2019 expansion, including a proposed 30,000 sq. ft. automated greenhouse facility, extra vault space and security upgrades.
CROP also announced it has made a cannabis retail application in Chula Vista, California, for its Emerald Height’s brand and is working with its local partners to apply in additional municipalities.
CROP CEO, Michael Yorke, stated: “Having wide distribution of a premium organic Infused Cone with over 100,000 branded units and 125,000 pen cartridges set to be consumed in California, this is a major step forward for our brand portfolio and tenant farm.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact:
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1(604)484-4206
SOURCE Crop Infrastructure Corp.
- Published in Business, CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home
Crop Infrastructure’s Elite completes genetics lab
Momentum Public Relations
Press Release: January 23, 2019
Crop Infrastructure Corp.’s 49-per-cent-owned subsidiary, Elite Ventures, has completed its genetics, tissue culturing and micropropagation laboratory at the company’s Nevada tetrahydrocannabinol (THC) farm.
The lab will provide 10 million plant starts for the company’s 2,115 acres of cannabidiol (CBD) farms. By propagating in the lab, the company will save about $3.0-million in seed and planting costs for the 2019 season. In addition, the lab will also develop proprietary genetics to maximize yields and provide the company a production and quality lead with some 100 photocannabinoids, beginning with cannabinol (CBN) and cannabigerol (CBG).
The newly completed building will get its final inspection next week with the Cannabis Licensing Board for approval for recreational cannabis cultivation, production and commercial kitchen. The building blocks needed for the perimeter security wall have been ordered and are expected to be on site shortly for its construction.
Crop has announced a non-brokered private placement offering to raise up to $2-million by the issuance of up to 6,666,667 units at a price of 30 cents per unit. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercise price of 50 cents for a period of 24 months following the closing of the offering. Completion of the offering is subject to regulatory approval.
About Crop Infrastructure Corp.
Crop is focused on cannabis branding and real estate assets. The company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of cannabidiol farms, extraction in Nevada, and joint ventures on West Hollywood and San Bernardino dispensary apps, with international focuses in Jamaica and Italy.
- Published in CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home
Grown Rogue Expands into Michigan Cannabis Market
Momentum Public Relations
Press Release: January 15, 2019
Grown Rogue International Inc. (CSE:GRIN | OTC: NVSIF) (“Grown Rogue” or the “Company“), a vertically-integrated, multi-state cannabis company with licenses and operations in Oregon and California, has announced today the signing of a Memorandum of Understanding to expand its brand and products into Michigan through a strategic partnership with established local cannabis operators and investors. The expansion is anticipated to initially include two retail dispensaries, referred to as provisional centers in Michigan, a 19,000 sq ft indoor cultivation and processing center in Detroit, and an interest in a 28 acre parcel located in the northern portion of the lower peninsula which can be used for cultivation. Grown Rogue will make a further announcement relating to the definitive terms of the partnership which are currently being negotiated between the parties.
“We invested significant time looking for the right partners for our Michigan expansion,” stated Obie Strickler, CEO of Grown Rogue. “Our Michigan partners include executives with multi-generational leadership track records in real estate development and business investment throughout the State, as well as experienced cannabis operators.”
Strategically Located Assets
The proposed Detroit retail dispensary is strategically located in a highly desirable section of midtown Detroit in close proximity to popular Detroit sports stadiums, art centers, and central to a fast growing affluent housing district. The Hazel Park location is within ¼ mile of the busiest freeway systems in the State as well as central to several popular destination Cities in Royal Oak, Birmingham, Ferndale, and Madison Heights. Hazel Park is only issuing a total of four provisioning center licenses.
The 19,000 sq ft Detroit cultivation center is a converted warehouse that is anticipated to house two (2) Class C growing licenses that will allow up to 3,000 plants for cultivation with an estimated annual production capacity of 2500 kgs. “Our cannabis experience includes an established brand presence, compliance and regulatory, construction of best-in-class cultivation facilities and other milestones we have achieved which will serve our partnership well as we continue to expand Grown Rogue nationally,” explained Mr. Strickler.
Early Mover Advantage
Michigan recently passed adult use cannabis in November 2018 with anticipated licensing for adult use beginning in early 2020 and has the second largest medical cannabis population in the United States. According to Detroitstats.com, in 2014, over 1 million people were recorded to have used marijuana (15.6% of the population) in Michigan. While California had over 4 million residents that said they consumed marijuana in 2016 (14.9% of the population).
“There is already such a significant adoption of cannabis by the general population in Michigan that we can really hit the ground running with our established brand and proven business processes,” said Jacques Habra, Chief Strategy Officer of Grown Rogue. “This strategic partnership, in one of most exciting states in the US, continues our focus on building a multi-state cannabis company.”
The barriers to entry into the Michigan cannabis industry are high due to regulatory standards still in flux and limitations on licensing by municipality. Grown Rogue’s momentum and multiple assets provide a unique advantage.
“According to the Detroit Free Press, Michigan has the second highest medical cannabis patient population at 283,832, which is the the highest percentage per capita in the United States. We are excited to take advantage of this new market opportunity for Grown Rogue’s proven business model,” added Mr. Strickler.
About Grown Rogue
Grown Rogue International (CSE: GRIN | OTC: NVSIF) is a vertically-integrated, multi-state cannabis company curating innovative products to provide consumers with the right cannabis experience. Each of Grown Rogue’s products and strains are categorized and marketed based on unique effects and designed for the full range of a consumers’ lifestyle. Grown Rogue is scaling the vertically integrated model into multiple states by incorporating best-in-class manufacturing facilities and a proprietary distribution platform based on Microsoft technology. Grown Rogue’s diverse cannabis product suite includes premium flower, patent-pending nitrogen sealed pre-rolls, oil and concentrates, and edibles featuring a partnership with world-renowned chocolatier, Jeff Shepherd.
Subscribe to Grown Rogue investor news alerts.
- Published in Cannabis, Grown Rogue, Marijuana, Medical Marijuana, News Home
Grown Rogue Appoints Adam Wolf as Chief Operating Officer
Momentum Public Relations
Press Release: January 3, 2019
Grown Rogue International Inc. (CSE : GRIN) (“Grown Rogue” or the “Company“), announces the appointment of Mr. Adam Wolf as Chief Operating Officer of the Company. Mr. Wolf has extensive operational and leadership experience which includes 15 years with Hyatt/Hilton Hotels and leadership roles at Teleflora – one of the largest subsidiaries of multi-billion dollar “The Wonderful Company.” Most recently he was Chief Operating Officer for MarijuanaPackaging.com, the largest privately held packaging and supply company in the cannabis industry where he led and directed all facets of operations. He has also been responsible for overseeing sales and marketing in his executive roles, driving brand recognition and a solid track record for achieving sales growth and profitability targets.
Mr. Wolf takes over the role from Obie Strickler, CEO of Grown Rogue, who had been functioning as the Company’s interim COO. Mr. Strickler commented on the appointment, “We carefully searched for the right candidate that could bring operational management expertise coupled with understanding the fast growing cannabis industry. We have found this in Adam who has tremendous management experience and unique cannabis specific knowledge that he brings to the Grown Rogue team. ”
“I am thrilled to join an established leader in the cannabis industry in Grown Rogue,” said Mr. Wolf. “I explored several professional opportunities in the cannabis industry and Grown Rogue’s level of excellence in branding, cultivation, and most importantly expansion targets, was the difference maker. I look forward to applying my experience and knowledge to help Grown Rogue expand relationships in our existing markets and continue to scale into additional states.”
Mr. Wolf earned a B.B.A. from The George Washington University and an M.B.A. from The UCLA Anderson School of Management, where he graduated in the top of his graduating class in both programs with a focus on Strategy and Operations.
About Grown Rogue
Grown Rogue International (CSE: GRIN) is a vertically-integrated, multi-state cannabis company curating innovative products to provide consumers with their desired cannabis experiences. Each of Grown Rogue’s products and strains are categorized and marketed according their unique effects. The Company’s “seed to experience” branding conveys its vision of ensuring “the right experience, every time”. Grown Rogue is scaling its model into multiple states incorporating best in class manufacturing facilities and a proprietary distribution platform based on exclusively licensed Microsoft technology. Grown Rogue’s diverse cannabis product suite includes premium flower, patent-pending nitrogen sealed pre-rolls, oil and concentrates, and edibles featuring a partnership with a world-renowned chocolatier.
Subscribe to Grown Rogue investor news alerts.
- Published in Cannabis, Grown Rogue, Marijuana, Medical Marijuana, News Home